β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study

Virchows Archiv

Volumn 467, Issue 5, 2015, Pages 535-542

  Ando, Sumiyo ^a   Shibahara, Junji ^a   Hayashi, Akimasa ^a   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Glutamine synthetase; Hepatocellular carcinoma; Non alcoholic fatty liver disease; Sonic hedgehog; Steatohepatitis; catenin

Indexed keywords

BETA CATENIN; EPITHELIAL CELL ADHESION MOLECULE; GLUTAMATE AMMONIA LIGASE; PROTEIN; SAL LIKE PROTEIN 4; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; SHH PROTEIN, HUMAN;

ARTICLE; CANCER INCIDENCE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; CARCINOMA, HEPATOCELLULAR; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; GLUTAMATE-AMMONIA LIGASE; HEDGEHOG PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MUTATION; PHENOTYPE;

EID: 84948095600     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1836-2     Document Type: Article

References (35)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi:10.1002/ijc.29210
2. Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijioka T, Katayama K, Yabuuchi I, Yoshihara H, Inoue A, Kato M, Takehara T, Tamura S, Kasahara A, Hayashi N, Tsukuma H (2008) Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 148:820–826
3. Yuen MF, Hou JL, Chutaputti A, Carcinoma APWPoPoH (2009) Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24:346–353. doi:10.1111/j.1440-1746.2009.05784.x
4. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51:1820–1832. doi:10.1002/hep.23594
5. Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 56:1384–1391. doi:10.1016/j.jhep.2011.10.027
6. Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH (2010) Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34:1630–1636. doi:10.1097/PAS.0b013e3181f31caa
7. Salomao M, Remotti H, Vaughan R, Siegel AB, Lefkowitch JH, Moreira RK (2012) The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43:737–746. doi:10.1016/j.humpath.2011.07.005
8. Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M (2014) Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 64:951–962. doi:10.1111/his.12343
9. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847
10. Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A (2012) Gene signatures in the management of hepatocellular carcinoma. Semin Oncol 39:473–485. doi:10.1053/j.seminoncol.2012.05.003
11. Moeini A, Cornellà H, Villanueva A (2012) Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 1:83–93. doi:10.1159/000342405
12. Michelotti GA, Machado MV, Diehl AM (2013) NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10:656–665. doi:10.1038/nrgastro.2013.183
13. Hayashi A, Yamauchi N, Shibahara J, Kimura H, Morikawa T, Ishikawa S, Nagae G, Nishi A, Sakamoto Y, Kokudo N, Aburatani H, Fukayama M (2014) Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior. PLoS One 9:e91330. doi:10.1371/journal.pone.0091330
14. Maeda D, Shibahara J, Sakuma T, Isobe M, Teshima S, Mori M, Oda K, Nakagawa S, Taketani Y, Ishikawa S, Fukayama M (2011) β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors. Am J Surg Pathol 35:1429–1440. doi:10.1097/PAS.0b013e31822d6c71
15. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. doi:10.1038/bmt.2012.244
16. Nejak-Bowen KN, Monga SP (2011) Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol 21:44–58. doi:10.1016/j.semcancer.2010.12.010
17. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788. doi:10.1158/0008-5472.CAN-08-0742
18. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM (2012) Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18:4997–5007. doi:10.1158/1078-0432.CCR-11-2322
19. Audard V, Grimber G, Elie C, Radenen B, Audebourg A, Letourneur F, Soubrane O, Vacher-Lavenu MC, Perret C, Cavard C, Terris B (2007) Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations. J Pathol 212:345–352. doi:10.1002/path.2169
20. Dal Bello B, Rosa L, Campanini N, Tinelli C, Torello Viera F, D’Ambrosio G, Rossi S, Silini EM (2010) Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res 16:2157–2166. doi:10.1158/1078-0432.CCR-09-1978
21. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42–52. doi:10.1002/hep.21467
22. Burke ZD, Reed KR, Phesse TJ, Sansom OJ, Clarke AR, Tosh D (2009) Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent mechanism. Gastroenterology 136:2316–2324. doi:10.1053/j.gastro.2009.02.063, e2311–2313
23. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM (2012) Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 18:4997–5007
24. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A (2009) Adipogenesis and WNT signalling. Trends Endocrinol Metab 20:16–24. doi:10.1016/j.tem.2008.09.002
25. Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ (2014) Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci 59:365–374. doi:10.1007/s10620-013-2873-9
26. Huang S, He J, Zhang X, Bian Y, Yang L, Xie G, Zhang K, Tang W, Stelter AA, Wang Q, Zhang H, Xie J (2006) Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27:1334–1340. doi:10.1093/carcin/bgi378
27. Efroni S, Meerzaman D, Schaefer CF, Greenblum S, Soo-Lyu M, Hu Y, Cultraro C, Meshorer E, Buetow KH (2013) Systems analysis utilising pathway interactions identifies sonic hedgehog pathway as a primary biomarker and oncogenic target in hepatocellular carcinoma. IET Syst Biol 7:243–251
28. Jung Y, Witek RP, Syn WK, Choi SS, Omenetti A, Premont R, Guy CD, Diehl AM (2010) Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59:655–665. doi:10.1136/gut.2009.204354
29. Rangwala F, Guy CD, Lu J, Suzuki A, Burchette JL, Abdelmalek MF, Chen W, Diehl AM (2011) Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 224:401–410. doi:10.1002/path.2888
30. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, Koike K, Kaufman RJ, Karin M (2014) ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26:331–343. doi:10.1016/j.ccr.2014.07.001
31. Amakye D, Jagani Z, Dorsch M (2013) Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 19:1410–1422. doi:10.1038/nm.3389
32. Rountree CB, Mishra L, Willenbring H (2012) Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 55:298–306. doi:10.1002/hep.24762
33. Guerrieri F, Belloni L, Pediconi N, Levrero M (2013) Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis 33:147–156. doi:10.1055/s-0033-1345721
34. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA (2011) Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 71:3701–3708. doi:10.1158/0008-5472.CAN-10-3951
35. Lee D, Do IG, Choi K, Sung CO, Jang KT, Choi D, Heo JS, Choi SH, Kim J, Park JY, Cha HJ, Joh JW, Choi KY, Kim DS (2012) The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol 25:131–139. doi:10.1038/modpathol.2011.133